Rapamycin amplifies the endurance post-exercise response of PGC-1α gene expression (creation of new mitochondria))

#1

That’s a cool paper from Keith Baar (A tendons/skeletal muscles authority)

Basically for mitochondria endurance training is not affected by rapamycin and even increased!

Rapamycin did not block PGC-1α transcriptional response post-exercise.[…] PGC-1α gene expression was enhanced to a greater extent after rapamycin treatment at each post-exercise timepoint. A similar pattern was observed for PDK4 and, to a lesser degree, TFAM. Taken together, these data indicate that mTORC1 activity is not a pre-requisite for exercise-induced activation of PGC-1α or increases in post-exercise PGC-1α function.

image
image2342×1220 448 KB

2 Likes
#2

This is the paper I think, from 2015:

Rapamycin does not prevent increases in myofibrillar or mitochondrial protein synthesis following endurance exercise

1 Like
#3

Yes, this is it, I forgot to add the link.

1 Like
#4

OK - I made a layman friendly summary available of this research here: The Anabolic-Catabolic Paradox: A Unified Theory of Longevity and Exercise Physiology

#5

Interesting. However, it’s important to note, this was in female mice.

1 Like
#6

Longevity.Technology: It’s easy to see why the longevity field is getting excited about PGC-1α. A wealth of research has indicated the protein’s role in everything from mitochondrial function and autophagy, to whole-body metabolic fitness – all key factors when it comes to addressing age-related decline. While Endurance Bio is initially pursuing neurodegenerative diseases, the company sees PGC-1α less as a disease-specific target and more as a “metabolic integrator” whose modulation could, in principle, impact multiple age-related diseases. To learn more, we sat down with Endurance’s Frederic Godderis, who founded the company alongside former Tranquis execs Sanjay Kakkar, Enchi Liu and Andrew Lam.